PRCT PROCEPT BioRobotics Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1588978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY-35.8%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin64.7%
Operating margin-33.6%
Net margin-32.6%
FCF margin-24.1%
EBITDA margin-31.3%
Returns
ROE-32.4%
ROA-23.3%
ROIC (approx.)-62.4%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets30.6%
Debt / equity0.16x
Current ratio5.89x
Interest coverage-34.73x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $308.05M | $224.50M | $136.19M | $75.01M | $34.47M |
| Cost of revenue | $111.83M | $87.40M | $65.14M | $37.93M | $18.61M |
| Gross profit | $196.23M | $137.10M | $71.05M | $37.09M | $15.87M |
| R&D expense | $71.28M | $62.30M | $48.45M | $28.98M | $18.99M |
| SG&A expense | $228.81M | $171.41M | $131.77M | $88.83M | $51.04M |
| Operating income | -$103.86M | -$96.61M | -$109.17M | -$80.72M | -$54.16M |
| Interest expense | $3.59M | $4.18M | $4.00M | $5.18M | $5.81M |
| Pretax income | -$95.38M | -$91.05M | -$105.82M | — | — |
| Income tax | $190,000 | $368,000 | $80,000 | $0 | $0 |
| Net income | -$95.57M | -$91.41M | -$105.90M | -$87.15M | -$59.85M |
| EBITDA | -$97.47M | -$91.38M | -$105.36M | -$77.88M | -$50.84M |
| EPS (basic) | -1.72 | -1.75 | -2.24 | -1.96 | -3.63 |
| EPS (diluted) | -1.72 | -1.75 | -2.24 | -1.96 | -3.63 |
| Weighted avg. shares (diluted) | 55.54M | 52.12M | 47.26M | 44.40M | 16.48M |
| Banking | |||||
| Provision for credit losses | — | $840,000 | $0 | $0 | — |
| Balance sheet | |||||
| Cash & equivalents | $286.50M | $336.76M | $257.22M | $225.67M | $305.10M |
| Receivables | $83.53M | $83.50M | $48.38M | $15.27M | $4.46M |
| Inventory | $70.69M | $56.17M | $39.76M | $28.54M | $13.15M |
| Current assets | $450.38M | $481.84M | $350.57M | $272.63M | $326.17M |
| PP&E, net | $30.40M | $26.71M | $28.75M | $8.66M | $5.04M |
| Total assets | $508.08M | $534.02M | $404.72M | $309.33M | $337.02M |
| Current liabilities | $65.80M | $53.13M | $45.93M | $35.29M | $16.24M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | $51.62M | $51.47M | $51.34M | $51.21M | $50.00M |
| Total debt | $51.62M | $51.47M | $51.34M | $51.21M | $50.00M |
| Total liabilities | $142.21M | $131.80M | $123.97M | $112.26M | $69.93M |
| Shareholders' equity | $365.87M | $402.22M | $280.75M | $197.07M | $267.09M |
| Net debt | -$234.89M | -$285.29M | -$205.88M | -$174.46M | -$255.09M |
| Shares outstanding | 56.32M | 54.72M | 50.77M | 44.83M | 43.68M |
| Cash flow statement | |||||
| Operating cash flow | -$48.98M | -$99.21M | -$108.00M | -$80.38M | -$57.33M |
| Capital expenditure | $9.36M | $4.41M | $25.21M | $2.65M | $592,000 |
| Free cash flow | -$58.34M | -$103.62M | -$133.21M | -$83.03M | -$57.93M |
| Investing cash flow | -$9.36M | -$4.41M | -$25.21M | -$2.65M | -$592,000 |
| Financing cash flow | $11.19M | $180.12M | $167.79M | $3.61M | $262.12M |
| Depreciation & amortization | $6.39M | $5.23M | $3.81M | $2.84M | $3.32M |
| Stock-based compensation | $47.60M | $31.84M | $19.13M | $10.34M | $3.80M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.